CA2811734C - Multimeric il-15 soluble fusion molecules and methods of making and using same - Google Patents

Multimeric il-15 soluble fusion molecules and methods of making and using same Download PDF

Info

Publication number
CA2811734C
CA2811734C CA2811734A CA2811734A CA2811734C CA 2811734 C CA2811734 C CA 2811734C CA 2811734 A CA2811734 A CA 2811734A CA 2811734 A CA2811734 A CA 2811734A CA 2811734 C CA2811734 C CA 2811734C
Authority
CA
Canada
Prior art keywords
15rasu
complex
cells
domain
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2811734A
Other languages
English (en)
French (fr)
Other versions
CA2811734A1 (en
Inventor
Hing C. Wong
Peter Rhode
Bai LIU
Xiaoyun Zhu
Kai-Ping Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altor Bioscience LLC
Original Assignee
Altor Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience LLC filed Critical Altor Bioscience LLC
Publication of CA2811734A1 publication Critical patent/CA2811734A1/en
Application granted granted Critical
Publication of CA2811734C publication Critical patent/CA2811734C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
CA2811734A 2010-09-21 2011-09-21 Multimeric il-15 soluble fusion molecules and methods of making and using same Active CA2811734C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38481710P 2010-09-21 2010-09-21
US61/384,817 2010-09-21
US201161527911P 2011-08-26 2011-08-26
US61/527,911 2011-08-26
PCT/US2011/052545 WO2012040323A2 (en) 2010-09-21 2011-09-21 Multimeric il-15 soluble fusion molecules and methods of making and using same

Publications (2)

Publication Number Publication Date
CA2811734A1 CA2811734A1 (en) 2012-03-29
CA2811734C true CA2811734C (en) 2021-11-23

Family

ID=45874349

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2811734A Active CA2811734C (en) 2010-09-21 2011-09-21 Multimeric il-15 soluble fusion molecules and methods of making and using same

Country Status (12)

Country Link
US (11) US8507222B2 (OSRAM)
EP (5) EP2619229B1 (OSRAM)
JP (4) JP6251570B2 (OSRAM)
KR (2) KR20140020228A (OSRAM)
CN (3) CN105017429B (OSRAM)
AU (2) AU2011305476B2 (OSRAM)
CA (1) CA2811734C (OSRAM)
DK (3) DK3327040T3 (OSRAM)
ES (2) ES2579077T3 (OSRAM)
HK (1) HK1249533A1 (OSRAM)
PT (2) PT2619229T (OSRAM)
WO (1) WO2012040323A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845783B2 (en) 2010-09-21 2023-12-19 Altor BioScience, LLC. Multimeric IL-15 soluble fusion molecules and methods of making and using same

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
NZ703668A (en) 2007-06-27 2016-07-29 Us Sec Dep Of Health And Human Services Complexes of il-15 and il-15ralpha and uses thereof
WO2018112219A1 (en) * 2016-12-14 2018-06-21 Nant Holdings Ip, Llc Superkine
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CA3027071A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2013184938A2 (en) * 2012-06-08 2013-12-12 Alkermes. Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
NZ630790A (en) 2012-10-24 2016-11-25 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
BR112015013557B1 (pt) 2012-12-11 2021-12-14 Albert Einstein College Of Medicine Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
EP4032540A1 (en) 2013-04-19 2022-07-27 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
ES2828982T3 (es) * 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
LT3030262T (lt) * 2013-08-08 2020-03-10 Cytune Pharma Kombinuota farmacinė kompozicija
EP3995507B1 (en) 2013-08-08 2023-10-04 Cytune Pharma Il-15 and il-15ralpha sushi domain based on modulokines
JP7097667B2 (ja) 2013-09-27 2022-07-08 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体
CN105189562B (zh) * 2014-01-08 2019-08-16 上海恒瑞医药有限公司 Il-15异源二聚体蛋白及其用途
HUE057917T2 (hu) * 2014-01-15 2022-06-28 Kadmon Corp Llc Immunmodulátor szerek
CA3190002A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
CA2940570A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
EP2915569A1 (en) * 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2015164107A1 (en) 2014-04-23 2015-10-29 Emory University Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
PL3160498T3 (pl) * 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania
WO2016018920A1 (en) 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016081601A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
RU2711979C2 (ru) * 2014-12-19 2020-01-23 Цзянсу Хэнжуй Медсин Ко., Лтд. Белковый комплекс интерлейкина 15 и его применение
CN104830884A (zh) * 2015-01-22 2015-08-12 苏州大学 一种携带IL-15/sIL-15Ra融合基因的微环DNA表达载体的构建方法
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017027843A1 (en) 2015-08-12 2017-02-16 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
EP3352779A4 (en) * 2015-09-25 2020-02-19 Altor BioScience Corporation INTERLEUKIN-15-SUPERAGONIST FOR SIGNIFICANT REINFORCEMENT OF TRANSPLANT AGAINST TUMOR ACTIVITY
EP3359168A4 (en) * 2015-10-06 2019-08-07 Regents of the University of Minnesota THERAPEUTIC COMPOUNDS AND METHOD
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN108700566A (zh) 2016-02-19 2018-10-23 河谷控股Ip有限责任公司 免疫原性调节的方法
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
CA3019005A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
CN117362450A (zh) * 2016-05-27 2024-01-09 阿尔托生物科学有限公司 具有cd3结合域的基于多聚体il-15的分子的构造和表征
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2018011573A1 (en) * 2016-07-12 2018-01-18 Kymab Limited Animals, cells, ligands, polypeptides & methods
CA3042220A1 (en) * 2016-09-23 2018-03-29 The Regents Of The University Of California Autologous irradiated whole cell tumor vaccines lentivirally engineered to express cd80, il-15 and il-15 receptor alpha
CA3040504A1 (en) * 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
WO2018073365A1 (en) * 2016-10-19 2018-04-26 F. Hoffmann-La Roche Ag Method for producing an immunoconjugate
CA3041310C (en) 2016-10-21 2023-09-05 Altor Bioscience Corporation Multimeric il-15-based molecules
JP7250677B2 (ja) 2016-12-22 2023-04-03 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
CN108250301A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3046120A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
WO2018134784A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
KR102739572B1 (ko) * 2017-03-06 2024-12-10 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
KR102619015B1 (ko) 2017-03-15 2023-12-28 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
US20190048055A1 (en) * 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
CN110740747A (zh) 2017-06-20 2020-01-31 南克维斯特公司 Nk-92细胞和il-15激动剂联合治疗
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
AU2018297248A1 (en) * 2017-07-03 2020-02-20 Torque Therapeutics, Inc. Fusion molecules targeting immune regulatory cells and uses thereof
UA125971C2 (uk) 2017-07-25 2022-07-20 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
AU2018323455B2 (en) * 2017-08-28 2022-02-03 Altor Bioscience, Llc IL-15-based fusions to IL-7 and IL-21
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
US11905528B2 (en) 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
US20200384084A1 (en) 2017-12-01 2020-12-10 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
JP7386161B2 (ja) * 2017-12-19 2023-11-24 ブレイズ バイオサイエンス， インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
EP3735188A4 (en) 2018-01-05 2021-09-22 Theragi LLC SURGICAL FORCEPS AND DEPLOYMENT SYSTEM
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
RU2020128830A (ru) 2018-02-02 2022-03-03 Новартис Аг Комбинация агониста sting и il-15/il-15rа для лечения рака
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
AR114445A1 (es) 2018-02-26 2020-09-09 Synthorx Inc Conjugados de il-15, y sus usos
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
WO2019191100A1 (en) 2018-03-26 2019-10-03 Altor Bioscience Llc Anti-pdl1, il-15 and tgf-beta receptor combination molecules
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2019195420A1 (en) 2018-04-04 2019-10-10 Nant Holding IP, LLC Advanced avartar dendritic cells
IL310398A (en) 2018-04-18 2024-03-01 Xencor Inc Proteins from heterodimeric il-15/il-15rα fc and their uses
JP2021521784A (ja) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
EP3781597A1 (en) * 2018-04-18 2021-02-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
US11559044B2 (en) 2018-04-26 2023-01-24 Hoffmann-La Roche Inc. Method of and system for tracking an animal in a population of animals
CN110437339B (zh) 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
TWI809130B (zh) 2018-06-22 2023-07-21 美商凱特製藥公司 嵌合跨膜蛋白及其用途
CN121086085A (zh) * 2018-06-22 2025-12-09 科优基因公司 新型白介素-15 (il-15)融合蛋白及其用途
CN112654633B (zh) 2018-06-22 2025-05-09 科优基因公司 基于细胞因子的可生物活化药物及其使用方法
WO2020023713A1 (en) * 2018-07-26 2020-01-30 Nantbio, Inc. Tri-cytokine txm compositions and methods
WO2020024922A1 (zh) * 2018-07-30 2020-02-06 张晋宇 蛋白质异二聚体及其用途
WO2020037120A1 (en) * 2018-08-16 2020-02-20 Nantbio, Inc. Il7-il15 txm compositions and methods
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
AU2019328575B2 (en) * 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
CA3108949A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
US11701408B2 (en) 2018-10-11 2023-07-18 Nantcell, Inc. Treatment of immunosuppressed subjects
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
CN120535653A (zh) 2018-10-19 2025-08-26 明尼苏达大学董事会 Nk接合子分子及其使用方法
US20220111008A1 (en) 2018-12-13 2022-04-14 Jiangsu Hengrui Medicine Co., Ltd. Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
US11873338B2 (en) 2018-12-20 2024-01-16 Merus N.V. CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
AU2020206269A1 (en) * 2019-01-11 2021-08-05 Memorial Sloan Kettering Cancer Center Multimerization of IL-15/IL-15R-alpha-Fc complexes to enhance immunotherapy
WO2020150364A1 (en) * 2019-01-15 2020-07-23 Altor Bioscience, Llc Human immunodeficiency virus-specific t cell receptors
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US20220218789A1 (en) 2019-05-10 2022-07-14 Nant Holdings Ip, Llc Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
US12085571B2 (en) 2019-06-13 2024-09-10 Immunitybio, Inc. Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
JP7213976B2 (ja) 2019-07-08 2023-01-27 イミュニティーバイオ、インコーポレイテッド 単核細胞由来のｎｋ細胞
US11364291B1 (en) * 2019-07-18 2022-06-21 Nantcell, Inc. Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
CN110478474B (zh) * 2019-08-21 2020-06-02 启辰生生物科技(珠海)有限公司 免疫调节剂、疫苗、细胞及应用
CN114787196A (zh) * 2019-08-29 2022-07-22 南特生物科学公司 修饰的n-810及其方法
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2021113577A1 (en) * 2019-12-05 2021-06-10 Immune Targeting Inc. Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
CN114901698B (zh) * 2019-12-31 2024-08-06 纳夫罗根公司 抗肿瘤免疫抑制因子的工程化单克隆抗体的组合物和用途
AU2021205416A1 (en) 2020-01-08 2022-08-25 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
WO2021142476A1 (en) * 2020-01-12 2021-07-15 Dragonfly Therapeutics, Inc. Single-chain polypeptides
EP4097043A4 (en) * 2020-01-31 2024-05-22 Auragent Bioscience, LLC ULTRABRIGHT FLUORESCENT NANOCOMPOSITE STRUCTURES FOR IMPROVED FLUORESCENT BIOASSAYS
CA3168469A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressing il-15 heterodimers
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
EP4118109A1 (en) 2020-03-11 2023-01-18 NantCell, Inc. Proteinaceous therapeutics
WO2021202354A1 (en) * 2020-03-30 2021-10-07 Proviva Therapeutics (Hong Kong) Limited Il-2/il-15 compositions and methods of use thereof
CA3178895A1 (en) 2020-04-22 2021-10-28 Novartis Ag Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15)
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
US11318189B1 (en) 2020-05-13 2022-05-03 Nantcell, Inc. IL-15 agonist drug combinations for immune therapy
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
US12252525B2 (en) 2020-07-31 2025-03-18 Nantbio, Inc. Chimeric T cell receptors, nucleic acids, and methods of making and using the same
CN116437944A (zh) 2020-08-03 2023-07-14 南特细胞公司 Il-15超级激动剂的药物特异性药代动力学测定
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
IL301308A (en) * 2020-09-16 2023-05-01 Beigene Ltd INTERLEUKIN 15 structures and methods of use
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
JP2024501831A (ja) * 2020-12-23 2024-01-16 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法
CN113321736B (zh) * 2020-12-30 2024-01-09 苏州复融生物技术有限公司 一种长效化白介素15融合蛋白及其制备方法和应用
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
WO2022204267A1 (en) 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same
AU2022252307A1 (en) * 2021-03-31 2023-10-12 Anwita Biosciences, Inc. Fusion proteins, pharmaceutical compositions, and therapeutic applications
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
CN113321740B (zh) * 2021-05-08 2023-07-18 上海交通大学 一种融合蛋白及其制备方法和用途
EP4346875A4 (en) * 2021-05-28 2025-04-16 Akso Biopharmaceutical, Inc. BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15
CN117479831A (zh) 2021-06-09 2024-01-30 南特知识产权控股有限责任公司 用于在植物中生产感兴趣的蛋白质的方法和系统
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
US20240415964A1 (en) 2021-11-02 2024-12-19 Immunitybio, Inc. Natural killer cells for chordoma therapy
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
AU2023209440A1 (en) 2022-01-22 2024-07-04 Nantcell, Inc. Fusion molecules of ctla4 and il-15
CN116854821A (zh) 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
EP4335870A1 (en) 2022-09-06 2024-03-13 NantCell, Inc. Peptide therapeutics against sars-cov-2 spike protein
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024199355A1 (en) * 2023-03-29 2024-10-03 Starna Therapeutics Nucleic acids encoding therapeutic polypeptides and lipid nanoparticle composition comprising the nucleic acids
WO2024253944A2 (en) * 2023-06-06 2024-12-12 Jecho Laboratories, Inc. Interleukin-15 fusion protein and methods of use
WO2025010111A1 (en) * 2023-07-05 2025-01-09 Nanotein Technologies, Inc. Cell signaling complexes and uses thereof
TW202509219A (zh) 2023-07-13 2025-03-01 美商艾歐凡斯生物治療公司 編碼細胞介素之慢病毒載體及其用於製備腫瘤浸潤性淋巴球之用途
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
WO2025076124A1 (en) * 2023-10-02 2025-04-10 Immunitybio, Inc. Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
WO2025085672A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b
US20250134974A1 (en) * 2023-10-31 2025-05-01 Immunitybio, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
CN118108809B (zh) * 2024-03-15 2025-02-28 西湖实验室(生命科学和生物医学浙江省实验室) 一种跨膜荧光蛋白、水溶荧光蛋白及其用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687898B2 (ja) 1988-06-29 1994-11-09 株式会社ニッショー バルーンインフューザー
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
JPH09512165A (ja) 1994-04-06 1997-12-09 イミュネックス・コーポレーション インターロイキン１５
NZ266264A (en) 1994-04-06 1997-01-29 Immunex Corp Mammalian epithelium-derived t-cell factor called interleukin-15
US5580728A (en) 1994-06-17 1996-12-03 Perlin; Mark W. Method and system for genotyping
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6001973A (en) 1996-04-26 1999-12-14 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
DE69810091T2 (de) 1997-02-21 2003-10-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw., Zwijnaarde Verwendung von interleukin-15
WO2001056387A1 (en) 2000-02-01 2001-08-09 Donnell Michael A O Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
AU2001275246B2 (en) 2000-06-05 2006-06-29 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use thereof
CN1317301C (zh) * 2000-09-14 2007-05-23 贝斯以色列护理医疗中心有限公司 Il－2－和il－15－介导的t细胞应答的调节
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
US7043266B2 (en) 2002-02-04 2006-05-09 Sprint Spectrum L.P. Method and system for selectively reducing call-setup latency through management of paging frequency
WO2004028339A2 (en) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
JP4892335B2 (ja) * 2003-02-26 2012-03-07 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
DE10324708A1 (de) 2003-05-30 2004-12-16 Ltn Servotechnik Gmbh Schleifringelement und Verfahren zu dessen Herstellung
CN1233822C (zh) * 2003-09-05 2005-12-28 中国科学技术大学 白细胞介素－15基因修饰的自然杀伤细胞株及其制备方法
US8772451B2 (en) 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
EP1718670B1 (en) 2004-02-27 2011-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity
EP1586585A1 (de) 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
JP2008521406A (ja) 2004-11-24 2008-06-26 フレッド ハッチンソン キャンサー リサーチ センター 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法
MX2007006832A (es) 2004-12-13 2007-08-07 Cytos Biotechnology Ag Arreglos de antigeno interleucina 15 y usos de los mismos.
MX2007014474A (es) * 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
DE602006016765D1 (de) * 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere
US7965180B2 (en) * 2006-09-28 2011-06-21 Semiconductor Energy Laboratory Co., Ltd. Wireless sensor device
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
AU2013273643C1 (en) 2007-05-11 2016-08-11 Altor Bioscience Corporation Fusion molecules and il-15 variants
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
NZ703668A (en) * 2007-06-27 2016-07-29 Us Sec Dep Of Health And Human Services Complexes of il-15 and il-15ralpha and uses thereof
CN100478098C (zh) * 2007-07-03 2009-04-15 航天晨光股份有限公司 心形曲锥异形薄壁筒体无缝成型方法
WO2009117117A1 (en) 2008-03-19 2009-09-24 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use there of
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CN105017429B (zh) 2010-09-21 2021-04-06 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
US8779908B2 (en) 2012-07-16 2014-07-15 Shmuel Ur System and method for social dancing
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
NZ630790A (en) 2012-10-24 2016-11-25 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
ES2828982T3 (es) 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
PL3160498T3 (pl) 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania
CN104672325A (zh) 2015-03-11 2015-06-03 福建农林大学 一种用新鲜螺旋藻制备藻蓝蛋白的方法
KR101581763B1 (ko) 2015-06-22 2016-02-23 건국대학교 산학협력단 펄스 레이저 및 흡수계수가 높은 매질을 이용한 체성감각 유도 시스템
EP3352779A4 (en) 2015-09-25 2020-02-19 Altor BioScience Corporation INTERLEUKIN-15-SUPERAGONIST FOR SIGNIFICANT REINFORCEMENT OF TRANSPLANT AGAINST TUMOR ACTIVITY
JP2017198256A (ja) * 2016-04-26 2017-11-02 Nok株式会社 密封装置
CN117362450A (zh) 2016-05-27 2024-01-09 阿尔托生物科学有限公司 具有cd3结合域的基于多聚体il-15的分子的构造和表征

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845783B2 (en) 2010-09-21 2023-12-19 Altor BioScience, LLC. Multimeric IL-15 soluble fusion molecules and methods of making and using same

Also Published As

Publication number Publication date
JP2017093457A (ja) 2017-06-01
US10150805B2 (en) 2018-12-11
US9328159B2 (en) 2016-05-03
PT2918607T (pt) 2018-01-11
US9428573B2 (en) 2016-08-30
US11845783B2 (en) 2023-12-19
US20140205560A1 (en) 2014-07-24
CN105017429B (zh) 2021-04-06
US20160213750A1 (en) 2016-07-28
KR102070098B1 (ko) 2020-01-28
US20200181237A1 (en) 2020-06-11
EP4385570A3 (en) 2024-09-11
EP3327040A1 (en) 2018-05-30
WO2012040323A8 (en) 2012-08-09
DK2918607T3 (en) 2018-01-08
AU2017201056A1 (en) 2017-03-02
US20200190164A1 (en) 2020-06-18
CA2811734A1 (en) 2012-03-29
US20240076354A1 (en) 2024-03-07
US20140134128A1 (en) 2014-05-15
US20220002383A1 (en) 2022-01-06
CN103370339A (zh) 2013-10-23
DK2619229T3 (en) 2016-05-17
US12371472B2 (en) 2025-07-29
JP6408039B2 (ja) 2018-10-17
ES2579077T3 (es) 2016-08-04
JP6251570B2 (ja) 2017-12-20
US8507222B2 (en) 2013-08-13
AU2011305476A1 (en) 2013-04-11
KR20140020228A (ko) 2014-02-18
EP2619229B1 (en) 2016-04-06
US9255141B2 (en) 2016-02-09
HK1249533A1 (zh) 2018-11-02
AU2011305476B2 (en) 2016-12-01
EP3327040B1 (en) 2021-06-23
EP2918607A1 (en) 2015-09-16
EP2619229A4 (en) 2014-03-26
EP2918607B1 (en) 2017-11-08
EP4385570A2 (en) 2024-06-19
CN105017429A (zh) 2015-11-04
US11104716B2 (en) 2021-08-31
US20160355567A1 (en) 2016-12-08
JP2013541335A (ja) 2013-11-14
US11046747B2 (en) 2021-06-29
US10899821B2 (en) 2021-01-26
AU2017201056B2 (en) 2018-12-20
DK3327040T3 (da) 2021-09-20
CN103370339B (zh) 2017-12-26
US20140242025A1 (en) 2014-08-28
EP3851459A1 (en) 2021-07-21
JP2019033754A (ja) 2019-03-07
US20120177595A1 (en) 2012-07-12
WO2012040323A2 (en) 2012-03-29
US20190023766A1 (en) 2019-01-24
EP3851459B1 (en) 2024-05-01
JP2018046831A (ja) 2018-03-29
PT2619229T (pt) 2016-07-13
US10358478B2 (en) 2019-07-23
CN107880136A (zh) 2018-04-06
CN107880136B (zh) 2021-11-12
KR20180126632A (ko) 2018-11-27
WO2012040323A3 (en) 2012-06-21
EP2619229A2 (en) 2013-07-31
ES2651170T3 (es) 2018-01-24

Similar Documents

Publication Publication Date Title
CA2811734C (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
HK1190729B (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
HK1190729A (en) Multimeric il-15 soluble fusion molecules and methods of making and using same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151015